ZCZC
BFF-32
HEALTH-VIRUS-VACCINE
Desperately seeking a COVID-19 vaccine — the race is on
PARIS, July 17, 2020 (BSS/AFP) – Seven months after the emergence of
the worst global health crisis in a century the race is on to find the
medical equivalent of the Holy Grail — a COVID-19 vaccine.
To date the novel coronavirus has killed about 590,000 people
worldwide and infected close to 14 million in 196 countries since the
outbreak first emerged in China late last year.
How to stop in its tracks a pandemic which has wreaked havoc on the
world economy is now the pressing multi-billion-dollar issue for
vaccine developers aware that every suggestion the goal may be in
sight will be pored over in microscopic detail.
– How many vaccines? –
In its most recent assessment this month, the World Health
Organization identified 21 “vaccine candidates” — almost half
involving Chinese companies or institutes — following a series of
global clinical trials.
Many are still in what is termed the first phase, which seeks to
establish a product’s security and dosage.
Some however have graduated to phase two, which examines how
effective a medicine may be.
Two candidate vaccines have reached stage three, whereby developers
monitor issues such as degree of potential toxicity on a much larger
scale and test it in a wider range of conditions prior to eventual
submission for approval.
The duo concerned are a European project being developed at Oxford
University in tandem with AstraZeneca and a Chinese variant from
biopharmaceutical company Sinovac in collaboration with Brazilian
research institute Butantan.
Sinovac’s project is among the most advanced — it will start the
testing for its vaccine on volunteers in Brazil this month.
A Canadian clinical trial to involve CanSino Biologics was also
earlier given the green light, and the company said last month that
China’s military had approved for use within its ranks the vaccine it
helped to develop.
MORE/MRU/2040hrs
ZCZC
BFF-33
HEALTH-VIRUS-VACCINE-TWO
Sinopharm, which is working with the United Arab Emirates for
trials, finished construction of a new production facility with a
capacity of 100 million doses on July 1, Chinese authorities said on
social media.
Beyond the tests already under way the WHO is monitoring a further
139 potential vaccines which are still at the pre-clinical evaluation
stage, involving testing on animals.
Britain, Canada and the United States this week accused Moscow-linked
hackers of targeting labs in their countries conducting coronavirus
vaccine research.
– Which techniques? –
There’s a variety of approaches and techniques across proven or
experimental vaccines.
Some teams work on inactivated “classic” vaccines which use a virus
germ that has been “killed” while others, known as attenuated or
weakened varieties, involve using a live virus rendered less virulent.
Other types still include “sub-unit” vaccines, which contain a
fragment of the pathogen that it is derived from to produce an
appropriate immune response.
Then there are more innovative “viral vector” varieties which use
live viruses to deliver DNA into human cells to trigger an immune
response.
An example is to take a virus such as measles and, as the Pasteur
Institute is doing, modify it with a coronavirus protein and deploy it
against COVID-19.
Then there are new experimental developments involving gene-based
DNA or RNA vaccines using fragments of modified genetic material.
“The more candidate vaccines there are, and above all the more
types of candidate vaccines, the greater the chance of getting
somewhere” in terms of beating the virus, says Daniel Floret,
vice-president of France’s Technical Vaccination Committee.
– Results so far –
For now, only partial results have been made public, some dubbed
promising by the firms behind them.
MORE/MRU/2040hrs
ZCZC
BFF-34
HEALTH-VIRUS-VACCINE-THREE
Jean-FranØois Delfraissy, chairman of France’s scientific council
which has been guiding the French authorities on the issue throughout
the pandemic so far, said claims have to be closely probed as the
commercial effect of a potential, but unconfirmed, breakthrough can be
huge.
“There are considerable effects on the pharmaceutical industry from
an announcement which one has to view with the utmost caution,” the
immunologist told AFP.
“A vaccine injection (tested on) 30 people which gets announced as
a result — well, that’s not a result,” Delfraissy noted.
Floret agreed that many announcements are directed at least as much
at the stock market as at the general public.
“It’s never neutral. It is important they show us that they are
speeding things up but shall all the same have to see the results and
for the moment that’s not happening.”
– Going fast? –
All the while, with the pressure on to find a means of dealing with
the pandemic, procedures have been ramped up worldwide like never
before.
“Things are advancing at a rate of knots… and projects are going
along perhaps a bit quicker than forecast,” Christophe d’Enfert, from
the Pasteur Institute, told AFP.
States and large foundations alike have been falling over
themselves to push fundraising efforts.
And while the United States has been looking to go it alone, Europe
and most other countries are looking at cooperation.
The Trump administration has set up “Operation Warp Speed” in a bid
to deliver 300 million doses, essentially for US citizens, of a safe,
effective vaccine for COVID-19 by January.
Firms “are trying to develop a vaccine and at the same time put in
place an industrial process to produce it whereas normally you wait to
see the results” of the first of those operations, notes Delfraissy.
MORE/MRU/2040hrs
ZCZC
BFF-35
HEALTH-VIRUS-VACCINE-FOUR LAST
“That’s why they are calling on states for financing, saying: ‘We
are taking a risk starting off on (developing) a vaccine which maybe
won’t work and if we put in place the industrial (production) process
we shall have to be partially covered by international financing.”
– Security problems –
“To authorise any COVID-19 vaccine, EMA will need to have strong
evidence from clinical trials on the safety, efficacy and the quality
of this vaccine,” warns the European Medicines Agency, an EU body.
Forcing the pace in clinical trials “can cause problems” regarding
security, says Floret, who says it is “key to have proof that the
vaccine is not liable to exacerbate the illness”.
That, he recalls, did happen in some tests on monkeys “during
vaccine development tests for MERS-CoV and SARS,” other strains of
coronavirus.
A similar problem arose in terms of some measles tests on humans in
the 1960s which were withdrawn as well as some for bronchiolitis that
were likewise abandoned, says Floret. – How long? –
EMA warns that “vaccine development timelines are difficult to predict”.
Based on previous development timelines, it said it may take until
next year before a COVID-19 vaccine is ready for widespread use.
Even so, some firms are optimistic they can turn up trumps before
the end of this year.
In Floret’s view, “I am not that sure it is very realistic (to say)
a vaccine will be there by the autumn — we have to temper such
enthusiasm.”
He believes the first quarter of next year is likelier and “if we get
there by then we shall already have done extremely well,” given the
usual development timeline is several years.
– How about never? –
The world is now awaiting a vaccine as it were a kind of messiah as
the only infallible means of defeating the pandemic.
But what if one never arrives?
Delfraissy said: “We have never perfected a vaccine against a
coronavirus, even if we have never completely given ourselves the
means to do so.
“There is a degree of uncertainty over our capacity to perfect a
vaccine against coronavirus, — but all the elements to get there are
in place,” he stressed.
“Everything is possible, the maximum means and different techniques
envisaged are out there and it would be astonishing if we didn’t get
there,” Floret said.
Yet even if the researchers arrive at the finish line a large
question will still remain — will people accept being vaccinated in a
world where there is growing mistrust of vaccination?
Perhaps not.
“As repeated measles outbreaks demonstrate, we haven’t done a great
job addressing people’s concerns about vaccines. And if we don’t learn
from our failed response to them, a coronavirus vaccine program will
be doomed,” Phoebe Danziger, a paediatrician at the University of
Michigan, told the New York Times.
BSS/AFP/MRU/2040hrs